Product Promotion Network

Most of the Intended Management Changes After

  1. Ken Herrmann[16]1,7
  1. 1Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California

  2. 2Department of Endocrinology, UCLA, Los Angeles, California

  3. 3Department of Oncology, Cedars-Sinai Medical Center, Los Angeles, California

  4. 4Division of Gastroenterology and Hepatology, VAGLAHS, and Departments of Medicine and Human Genetics, UCLA, Los Angeles, California

  5. 5Department of Oncology, UCLA, Los Angeles, California

  6. 6Department of Oncology, Montefiore Einstein Center for Cancer Care, New York, New York; and

  7. 7Department of Nuclear Medicine, Universit?tsklinikum Essen, Essen, Germany

  1. For correspondence or reprints contact: Jeremie Calais, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Medical Plaza 200, Suite B114-61, Los Angeles, CA 90095. E-mail: jcalais{at}mednet.ucla.edu

Abstract

In this prospective referring-physician-based survey, we investigated the definite clinical impact of 68Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with 68Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679[17]).

Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). 68Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%).

Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of 68Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

Keywords

Footnotes

  • Guest Editor: David A. Mankoff, University of Pennsylvania.

  • Published online May 4, 2017.

  • (C) 2017 by the Society of Nuclear Medicine and Molecular Imaging.

References

  1. ^ Jeremie Calais (jnm.snmjournals.org)
  2. ^ Johannes Czernin (jnm.snmjournals.org)
  3. ^ Matthias Eiber (jnm.snmjournals.org)
  4. ^ Wolfgang P. Fendler (jnm.snmjournals.org)
  5. ^ Jeannine Gartmann (jnm.snmjournals.org)
  6. ^ Anthony P.

    Heaney (jnm.snmjournals.org)

  7. ^ Andrew E. Hendifar (jnm.snmjournals.org)
  8. ^ Joseph R. Pisegna (jnm.snmjournals.org)
  9. ^ J.

    Randolph Hecht (jnm.snmjournals.org)

  10. ^ Edward M.

    Wolin (jnm.snmjournals.org)

  11. ^ Roger Slavik (jnm.snmjournals.org)
  12. ^ Pawan Gupta (jnm.snmjournals.org)
  13. ^ Andrew Quon (jnm.snmjournals.org)
  14. ^ Christiaan Schiepers (jnm.snmjournals.org)
  15. ^ Martin S.

    Allen-Auerbach (jnm.snmjournals.org)

  16. ^ Ken Herrmann (jnm.snmjournals.org)
  17. ^ NCT02174679 (jnm.snmjournals.org)

Leave a Reply

Your email address will not be published. Required fields are marked *

Categories